Pharma Industry News

Oxford BioDynamics signs deal to develop ASD biomarkers

Oxford BioDynamics, Italian research institute pair to develop biomarkers for autism spectrum disorder (ASD).Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]